• Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
    • Photo Gallery
  • Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
      • ASH 2018 – San Diego
      • Stockholm 2018
      • ASH 2017 – Atlanta, GA
      • Madrid 2017
      • ASH 2016
      • Copenhagen 2016
      • ASH 2015
      • Vienna 2015
      • ASH 2014
      • Milan 2014
    • Photo Gallery

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

By imwgimf On December 29, 2015 · Add Comment · In Relapse
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and […]
Read More »

Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

By imwgimf On September 28, 2015 · Add Comment · In IMWG Publications, Transplant
In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward.
Read More »
 
  • Popular
  • Recent
  • Comments
  • Tags
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe updated criteria for the diagnosis of myeloma represent a [...]
  • International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma
  • IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
  • Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupWhole Body Low Dose CT (WBLDCT) has important advantages as [...]
  • Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American CountriesLatin American countries (LATAMC) represent a large fraction of patients [...]
  • Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupFor decades conventional skeletal survey (CSS) has been the standard [...]
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG studyIntroduction of new myeloma therapies offers new options for patients [...]
ASCT bone disease bortezomib classification computed tomography consensus cytogenetics diagnosis DVT genetic guidelines IMWG International myeloma working group International Staging System ISS lenalidomide magnetic resonance imaging molecular multiple myeloma myeloma patients prognosis response criteria stem cell survival thalidomide therapy thrombosis transplantation treatment
  • Categories

    • Diagnosis, Staging & Monitoring
    • Guidelines
    • IMWG Publications
    • Maintenance
    • Relapse
    • Supportive Care
    • Transplant
    • Treatment Options
  • Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
    To find out more, including how to control cookies, see here: Cookie Policy
  • Search

 
© 2019 IMWG